Related Experiment Video
Updated: Mar 7, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
[Research progress on disease models and gene therapy of Duchenne muscular dystrophy]
1Division of Hepatobilitary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine;Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health;Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China; Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China.
Abstract:
Duchenne muscular dystrophy (DMD) is an X-linked, recessive and lethal genetic disease, which usually caused by gene mutations and the underlying mechanisms are complicated and diverse. The causal gene of DMD is the largest one in human that locates in the region of Xp21.2, encoding dystrophin. Currently there is no effective treatment for DMD patients. The treatment of DMD depends on gene mutation and molecular mechanism study of the disease, which requires reliable disease models such as mdx mouse model. Recently, researchers have increasingly discovered gene therapy strategies for DMD, and the efficacy has been demonstrated in DMD animal models. In addition, induced pluripotent stem cell technology can provide patient-specific cell source, offering a new platform for mechanism and therapy study of DMD.
More Related Videos
Related Concept Videos
Gene Therapy
Satellite Stem Cells and Muscular Dystrophy
EPS and iPS Cells in Disease Research
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

